• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dario Signs First Healthcare System as Employer Contract, Expanding Market Presence and Recurring Revenue Growth

    3/5/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care
    Get the next $DRIO alert in real time by email

    Healthcare system collaborates with Dario to offer AI-powered chronic care management solutions as a benefit for their employee base of healthcare workers, expected to contribute to the current total of 15 new client signings in 2025, representing a significant head start in its 2025 net new client goal.

    NEW YORK, March 5, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the signing of a contract with a major healthcare system to be added to its employer book of business, set to go live in the first quarter of 2025. We believe that this milestone reinforces the growing recognition of digital health solutions among healthcare professionals, a group uniquely positioned to understand the value of proactive, technology-driven care.

    DarioHealth Corp. Logo

    The new healthcare system contract marks a significant step for Dario. As self-insured employers, these organizations carefully evaluated Dario's ability to deliver measurable value for both employees and patients. Their decision to integrate Dario's solutions reflects confidence in the company's ability to enhance care delivery while addressing chronic conditions such as diabetes, hypertension, musculoskeletal (MSK) pain, and mental health challenges.

    Dario aims to position itself at the forefront of the evolution of the digital health landscape, demonstrating the ability of digital health solutions to drive meaningful clinical outcomes. Peer-reviewed studies highlight Dario's effectiveness in reducing A1C levels for diabetes patients by 2.3 points, as well as decreasing anxiety and depression by 28-30% over eight weeks through its behavioral health platform, Dario Mind. By combining AI-driven personalization with a seamless user experience, Dario is closing the gap between traditional care models and scalable digital interventions.

    "We are thrilled to add such a unique segment to our employer book of business," said Steven Nelson, Chief Commercial Officer at Dario. "Healthcare workers have a deep understanding of the impact that poor chronic condition management can have on a person. Having our solutions trusted by this audience is truly meaningful. These employers recognize the clinical importance of Dario's cardiometabolic and behavioral health solutions, and we are excited to provide them with tools that improve health outcomes and overall well-being."

    Historically, healthcare systems have been slower to adopt digital wellness and self-care therapies. Inconsistent reimbursement models and provider skepticism about engagement and clinical efficacy have all contributed to delayed integration. However, recent industry shifts—including coverage, stronger clinical evidence and more innovative approaches to engagement —are accelerating adoption.

    As the digital health landscape continues to evolve, collaborations with healthcare systems will play a critical role in expanding access to high-quality, technology-enabled care. By prioritizing innovation and clinical rigor, Dario remains committed to driving the next wave of digital health adoption for both employers and healthcare providers alike.

    About DarioHealth Corp.

    DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. 

    Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

    Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.

    Cautionary Note Regarding Forward-Looking Statements

    This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected timing for the new contract to be operational, the belief that this milestone reinforces the growing recognition of digital health solutions among healthcare professionals, the potential benefits of its platform and products and its belief that the new contract validates the need for digital health solutions among healthcare workers, and its ability to provide real clinical outcomes and create value for employees and their organizations alike. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    DarioHealth Corporate Contact

    Mary Mooney

    VP Marketing

    [email protected]

    +1-312-593-4280

    DarioHealth Investor Relations Contact 

    Kat Parrella

    Investor Relations Manager

    [email protected]

    +315-378-6922

    Logo: https://mma.prnewswire.com/media/1920436/3708722/DarioHealth_Logo.jpg

     

    Cision View original content:https://www.prnewswire.com/news-releases/dario-signs-first-healthcare-system-as-employer-contract-expanding-market-presence-and-recurring-revenue-growth-302393022.html

    SOURCE DarioHealth Corp.

    Get the next $DRIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRIO

    DatePrice TargetRatingAnalyst
    1/29/2025$2.00 → $1.00Buy → Hold
    TD Cowen
    5/13/2022$8.75Neutral → Buy
    Alliance Global Partners
    1/26/2022$28.00 → $25.00Buy
    Aegis Capital
    8/19/2021$35.00 → $28.00Buy
    Aegis Capital
    More analyst ratings

    $DRIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research

    Findings highlight the role of continuous behavioral support in improving focus, productivity and day-to-day functioning – key priorities for employers and health plansStatistically significant improvements in workplace functioning highlight the potential economic value of Dario's digital health solutions for payersNEW YORK, April 20, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of new peer-reviewed research in JMIR Formative Research demonstrating meaningful improvements in workplace functioning among participants using Dario's digital behavioral health program. The study, t

    4/20/26 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

    Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize its full strategic valueNEW YORK, April 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors.  The addition reflects Dario's continued alignment of board composition with its next phase of commercial scaling. Mr. Palumbo brings more than 40 ye

    4/13/26 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 20252025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $12.9 million in contracted and late stage, annual recurring revenue ("ARR")  set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectoryGAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-

    3/19/26 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CCO Nelson Steven Charles bought $21,200 worth of shares (40,000 units at $0.53), increasing direct ownership by 73% to 95,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    8/27/25 4:30:59 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Nelson Steven Charles bought $4,546 worth of shares (5,000 units at $0.91), increasing direct ownership by 10% to 55,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    11/14/24 4:15:15 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Nelson Steven Charles bought $8,244 worth of shares (10,000 units at $0.82), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/12/24 4:37:42 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    SEC Filings

    View All

    DarioHealth Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - DarioHealth Corp. (0001533998) (Filer)

    4/13/26 8:21:08 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by DarioHealth Corp.

    424B5 - DarioHealth Corp. (0001533998) (Filer)

    3/30/26 6:14:55 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - DarioHealth Corp. (0001533998) (Filer)

    3/30/26 5:31:40 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Palumbo John R

    3 - DarioHealth Corp. (0001533998) (Issuer)

    4/13/26 4:05:15 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    President and CCO Nelson Steven Charles was granted 30,000 shares, increasing direct ownership by 632% to 34,750 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 6:04:08 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Director Stern Adam K was granted 20,000 shares, increasing direct ownership by 206% to 29,717 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 6:03:10 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DarioHealth downgraded by TD Cowen with a new price target

    TD Cowen downgraded DarioHealth from Buy to Hold and set a new price target of $1.00 from $2.00 previously

    1/29/25 7:36:04 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth upgraded by Alliance Global Partners with a new price target

    Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75

    5/13/22 9:01:42 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Aegis Capital reiterated coverage on DarioHealth with a new price target

    Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously

    1/26/22 10:35:44 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Leadership Updates

    Live Leadership Updates

    View All

    Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

    Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize its full strategic valueNEW YORK, April 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors.  The addition reflects Dario's continued alignment of board composition with its next phase of commercial scaling. Mr. Palumbo brings more than 40 ye

    4/13/26 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Appoints Healthcare Industry Leader Larry Leisure to Board of Directors

    Healthcare innovator and former Accenture executive brings deep industry relationships to advance Dario's AI-driven chronic care platform. NEW YORK, Feb. 27, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in AI-driven digital health solutions, today announced the appointment of Lawrence (Larry) B. Leisure to its Board of Directors, bringing four decades of healthcare leadership, managed care expertise, and digital health innovation to the company's governance. Mr. Leisure's extensive experience working with health plans, health systems, consultants, and employer coalitions, combined with his deep understanding of health policy, reimbursement, and va

    2/27/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

    Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa

    10/28/24 4:44:00 PM ET
    $BMY
    $DRIO
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $DRIO
    Financials

    Live finance-specific insights

    View All

    DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 20252025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $12.9 million in contracted and late stage, annual recurring revenue ("ARR")  set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectoryGAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-

    3/19/26 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026

    Company to host conference call and webcast at 8:30 a.m. Eastern TimeNEW YORK, March 11, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 4th quarter ended December 31st, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Thursday, March 19th, 2026, before the market opens. Erez Raphael, Chief Executive Officer, Steven Nelson, President and Chief Commercial Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call.Conference Call DetailsDate: Thursday, March19th, 2026, 8:30 a.m. Eastern TimeDial-in Numb

    3/11/26 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Reports Third Quarter 2025 Financial and Operating Results

    Third quarter 2025 revenue was $5.0 million, compared to $7.4 million in the third quarter of 2024, and $5.4 million in the second quarter of 2025 Targeting $12.4 million in new business, reflecting both committed annual recurring revenue ("CARR") and late-stage opportunities nearing completion; 2026 pipeline expanded to $69 millionExceeded 2025 goal of 40 new signed accounts for 2026 revenue, with 45 new signed accounts to date—several already contributing to 2025 results; average employer customer size nearly doubled what was projectedStrong business fundamentals in the third quarter including GAAP gross margin increase to 60%, 7 consecutive quarters of 80%+ non-GAAP gross margins on core

    11/13/25 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    12/13/24 4:05:12 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    10/29/24 11:45:28 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DarioHealth Corp. (Amendment)

    SC 13G/A - DarioHealth Corp. (0001533998) (Subject)

    2/14/24 4:51:40 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care